Working Toward A Cure: Janssen’s Multiple Myeloma Strategy
T-cell Engagers, CAR-T Therapy Build On Darzalex Success
Janssen’s Mark Wildgust explained how the Johnson & Johnson subsidiary is pushing forward with novel therapeutics and combination regimens with the goal of eliminating myeloma in the first line.
